Transfer and loss of allergen-specific responses via stem cell transplantation: A prospective observational study.
IgE
bone marrow
clinical immunology
pediatrics
prevention
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
25
10
2019
revised:
31
01
2020
accepted:
10
02
2020
pubmed:
18
3
2020
medline:
15
5
2021
entrez:
18
3
2020
Statut:
ppublish
Résumé
Currently, no estimates can be made on the impact of hematopoietic stem cell transplantation on allergy transfer or cure of the disease. By using component-resolved diagnosis, we prospectively investigated 50 donor-recipient pairs undergoing allogeneic stem cell transplantation. This allowed calculating the rate of transfer or maintenance of allergen-specific responses in the context of stem cell transplantation. Allergen-specific IgE and IgG to 156 allergens was measured pretransplantation in 50 donors and recipients and at 6, 12 and 24 months in recipients post-transplantation by allergen microarray. Based on a mixed effects model, we determined risks of transfer of allergen-specific IgE or IgG responses 24 months post-transplantation. After undergoing stem cell transplantation, 94% of allergen-specific IgE responses were lost. Two years post-transplantation, recipients' allergen-specific IgE was significantly linked to the pretransplantation donor or recipient status. The estimated risk to transfer and maintain individual IgE responses to allergens by stem cell transplantation was 1.7% and 2.3%, respectively. Allergen-specific IgG, which served as a surrogate marker of maintaining protective IgG responses, was highly associated with the donor's (31.6%) or the recipient's (28%) pretransplantation response. Hematopoietic stem cell transplantation profoundly reduces allergen-specific IgE responses but also comes with a considerable risk to transfer allergen-specific immune responses. These findings facilitate clinical decision-making regarding allergic diseases in the context of hematopoietic stem cell transplantation. In addition, it provides prospective data to estimate the risk of transmitting allergen-specific responses via hematopoietic stem cell transplantation.
Sections du résumé
BACKGROUND
Currently, no estimates can be made on the impact of hematopoietic stem cell transplantation on allergy transfer or cure of the disease. By using component-resolved diagnosis, we prospectively investigated 50 donor-recipient pairs undergoing allogeneic stem cell transplantation. This allowed calculating the rate of transfer or maintenance of allergen-specific responses in the context of stem cell transplantation.
METHODS
Allergen-specific IgE and IgG to 156 allergens was measured pretransplantation in 50 donors and recipients and at 6, 12 and 24 months in recipients post-transplantation by allergen microarray. Based on a mixed effects model, we determined risks of transfer of allergen-specific IgE or IgG responses 24 months post-transplantation.
RESULTS
After undergoing stem cell transplantation, 94% of allergen-specific IgE responses were lost. Two years post-transplantation, recipients' allergen-specific IgE was significantly linked to the pretransplantation donor or recipient status. The estimated risk to transfer and maintain individual IgE responses to allergens by stem cell transplantation was 1.7% and 2.3%, respectively. Allergen-specific IgG, which served as a surrogate marker of maintaining protective IgG responses, was highly associated with the donor's (31.6%) or the recipient's (28%) pretransplantation response.
CONCLUSION
Hematopoietic stem cell transplantation profoundly reduces allergen-specific IgE responses but also comes with a considerable risk to transfer allergen-specific immune responses. These findings facilitate clinical decision-making regarding allergic diseases in the context of hematopoietic stem cell transplantation. In addition, it provides prospective data to estimate the risk of transmitting allergen-specific responses via hematopoietic stem cell transplantation.
Substances chimiques
Allergens
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2243-2253Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss M. The WAO White Book on Allergy. Milwaukee, WI: World Allergy Association; (Update 2013).
Gruber S, Dehlink E, Eiwegger T, et al. Immunoglobulin E-mediated allergies in lung-transplanted adults. Transplantation. 2007;84:275-279.
Dehlink E, Gruber S, Eiwegger T, et al. Immunosuppressive therapy does not prevent the occurrence of immunoglobulin E-mediated allergies in children and adolescents with organ transplants. Pediatrics. 2006;118:e764-e770.
Eiwegger T, Gruber S, Geiger C, et al. Impact of systemic immuno-suppression after solid organ transplantation on allergen-specific responses. Allergy. 2011;66:271-278.
Khan F, Hallstrand TS, Geddes MN, Henderson WR, Storek J. Is allergic disease curable or transferable with allogeneic hematopoietic cell transplantation? Blood. 2009;113:279-290.
Hallstrand TS, Sprenger JD, Agosti JM, Longton GM, Witherspoon RP, Henderson WR. Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors. Blood. 2004;104:3086-3090.
Agosti JM, Sprenger JD, Lum LG, et al. Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. N Engl J Med. 1988;319:1623-1628.
Brauns B, Schön MP, Wulf G, Mempel M. A lurking threat: transfer of peanut allergy through peripheral blood stem cell transplantation. World Allergy Organ J. 2016;9:3.
Garzorz N, Thomas J, Eberlein B, et al. Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwi-allergic donor. J Eur Acad Dermatol Venereol. 2016;30:1136-1139.
Lucke TW, Bong JL, Clark D, Murphy JA. Passive transfer of contact hypersensitivity to rubber following allogeneic bone marrow transplantation. Br J Dermatol. 1999;141:931.
Rietz H, Plummer AL, Gal AA. Asthma as a consequence of bone marrow transplantation. Chest. 2002;122:369-370.
Saarinen UM. Transfer of latent atopy by bone marrow transplantation? A case report. J Allergy Clin Immunol. 1984;74:196-200.
Shalit M, Amar A, Or R. Allergy development after bone marrow transplantation from a non-atopic donor. Clin Exp Allergy. 2002;32:1699-1701.
Storek J, Vliagoftis H, Grizel A, et al. Allergy transfer with hematopoietic cell transplantation from an unrelated donor. Bone Marrow Transplant. 2010;46:605.
Walker SA, Riches PG, Wild G, et al. Total and allergen-specific IgE in relation to allergic response pattern following bone marrow transplantation. Clin Exp Immunol. 1986;66:633-639.
Asher MI, Keil U, Anderson HR, et al. International study of asthma and allergies in childhood (ISAAC): rationale and methods. Eur Respir J. 1995;8:483-491.
Lupinek C, Wollmann E, Baar A, et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods. 2014;66:106-119.
Koharazawa H, Kanamori H, Takabayashi M, et al. Resolution of atopic dermatitis following allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant. 2005;35:1223.
O'B Hourihane J, Rhodes HL, Jones AM, Veys P, Connett GJ. Resolution of peanut allergy following bone marrow transplantation for primary immunodeficiency. Allergy. 2005;60:536-537.
Özdemir Ö. New developments in transplant-acquired allergies. World J Transplant. 2013;3:30-35.
Bhinder S, Heffer MJ, Lee JK, Chaparro C, Tarlo SM. Development of transient peanut allergy following lung transplantation: a case report. Can Respir J. 2011;18:154-156.
Dewachter P, Vezinet C, Nicaise-Roland P, et al. Passive transient transfer of peanut allergy by liver transplantation. Am J Transplant. 2011;11:1531-1534.
Khalid I, Zoratti E, Stagner L, Betensley AD, Nemeh H, Allenspach L. Transfer of peanut allergy from the donor to a lung transplant recipient. J Heart Lung Transplant. 2008;27:1162-1164.
Schuller A, Barnig C, Matau C, et al. Transfer of peanut allergy following lung transplantation: a case report. Transplant Proc. 2011;43:4032-4035.
Ching JCY, Lau W, Hannach B, Upton JEM. Peanut and fish allergy due to platelet transfusion in a child. CMAJ. 2015;187:905-907.
Depner M, Ege MJ, Genuneit J, et al. Atopic sensitization in the first year of life. J Allergy Clin Immunol. 2013;131(3):781-788.e9.
Happel CS, Stone KD, Freeman AF, et al. Food allergies can persist after myeloablative hematopoietic stem cell transplantation in DOCK8-deficient patients. J Allergy Clin Immunol. 2016;137:1895-1898.e5.
Marmont du Haut Champ AM. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:380391.
Griffith LM, Pavletic SZ, Tyndall A, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a national institute of allergy and infectious diseases and national cancer institute-sponsored international workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant. 2005;11:862-870.
Marmont AM. Allogeneic haematopoietic stem cell transplantation for severe autoimmune diseases: great expectations but controversial evidence. Bone Marrow Transplant. 2006;38:1-4.
Daikeler T, Hugle T, Farge D, et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 2009;44:27-33.
Ramaswamy S, Jain S, Ravindran V. Hematopoietic stem cell transplantation for auto immune rheumatic diseases. World J Transplant. 2016;6:199-205.
Illei GG. Hematopoietic stem cell transplantation in autoimmune diseases: is the glass half full or half empty? Arthritis Rheum. 2006;54:3730-3734.
Atkins HL, Freedman MS. Five questions answered: a review of autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14:888-893.
Papadaki HA, Tsagournisakis M, Mastorodemos V, et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. 2005;36:1053-1063.
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25:151-169.
Storek J, Viganego F, Dawson MA, et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood. 2003;101:3319-3324.
Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis. 1990;162:496-500.
Lum LG, Munn NA, Schanfield MS, Storb R. The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood. 1986;67:582-587.
Wahren B, Gahrton G, Linde A, et al. Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis. 1984;150:358-365.
Ogonek J, Verma K, Schultze-Florey C, et al. Characterization of high-avidity cytomegalovirus-specific T cells with differential tetramer binding coappearing after allogeneic stem cell transplantation. J Immunol. 2017;199:792-805.
Wimperis JZ, Prentice HG, Karayiannis P, et al. Transfer of a functioning humoral immune system in transplantation of t-lymphocyte-depleted bone marrow. Lancet. 1986;327:339-343.
Gottlieb D, Cryz SJ, Furer E, et al. Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients. Blood. 1990;76:2470-2475.
Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159:610-615.
Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood. 1994;84:657-663.
Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803-813.
Skrindo I, Lupinek C, Valenta R, et al. The use of the MeDALL-chip to assess IgE sensitization: a new diagnostic tool for allergic disease? Pediatr Allergy Immunol. 2015;26:239-246.
Siroux V, Lupinek C, Resch Y, et al. Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study. J Allergy Clin Immunol. 2017;139(2):643-654.e6.